2024
Nuclear Imaging of Bispecific Antibodies on the Rise
Roohani B, Mendez A, Dangarwala M, Katz S, Marquez-Nostra B. Nuclear Imaging of Bispecific Antibodies on the Rise. Journal Of Nuclear Medicine 2024, 65: 1512-1517. PMID: 39266295, PMCID: PMC11448611, DOI: 10.2967/jnumed.123.267215.Peer-Reviewed Original Research
2022
Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer
Li Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers 2022, 14: 2103. PMID: 35565232, PMCID: PMC9101155, DOI: 10.3390/cancers14092103.Peer-Reviewed Original ResearchPositron emission tomographyBreast cancerMolecular profilingTherapeutic targetSingle photon emission tomography (SPECT) imagingSelection of patientsNuclear imaging agentCustomization of therapyPrecision medicineImaging agentEmission Tomography ImagingMetastatic diseaseClinical evaluationClinical studiesClinical practiceClinical decisionEmission tomographyClinical researchStudy designCancerTomography imagingTherapyDifferent receptorsNoninvasive imagingSPECT agent
2021
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B. Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Frontiers In Pharmacology 2021, 12: 627693. PMID: 33986665, PMCID: PMC8111013, DOI: 10.3389/fphar.2021.627693.Peer-Reviewed Original ResearchDifferent molecular subtypesBreast cancerPositron emission tomographyMolecular subtypesEmission tomographySingle photon emission tomographyBreast cancer patientsResponse of therapyBreast cancer therapyNew therapeutic agentsPreclinical advancesMolecular imaging methodsCancer patientsCare treatmentCommon cancerPreclinical studiesTherapeutic strategiesCancerDrug resistanceTherapeutic agentsTherapyNew targetsCancer therapyPrecision medicinePatients
2019
Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy
Massicano AVF, Lee S, Crenshaw BK, Aweda TA, Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals 2019, 34: 209-217. PMID: 30676778, PMCID: PMC7227434, DOI: 10.1089/cbr.2018.2654.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell Line, TumorDeferoxamineFemaleHumansIsothiocyanatesMaytansineMiceMice, NudePositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2TrastuzumabTreatment OutcomeTumor BurdenX-Ray MicrotomographyXenograft Model Antitumor AssaysZirconiumConceptsT-DM1 therapyBreast cancerTumor volumeHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2BT-474 tumorsGrowth factor receptor 2HER2-positive tumorsFactor receptor 2HER2 expressionBCa patientsReceptor 2TherapyTumorsEarly responseBetter delineationPertuzumabPoor delineationMBq/MiceTreatmentResponsePatientsHER2
2018
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging 2018, 17: 1536012117745386. PMID: 29357745, PMCID: PMC5784567, DOI: 10.1177/1536012117745386.BooksConceptsHuman epidermal growth factor 2HER2 expressionHER2 statusEpidermal growth factor 2Treatment of patientsHER2-positive cancersWhole-body assessmentStandard diagnostic techniquesMetastatic settingGrowth factor 2Breast cancerClinical studiesNuclear medicineTumor fociInvasive biopsyAlternative treatmentTime of analysisSmall sample sizeTherapyNuclear imagingBiopsyPatientsFactor 2TumorsCancer